VTGNHealthcare · BiotechnologyThe 4 Wall Street analysts covering VistaGen Therapeutics, Inc. hold a median 12-month price target of $1 — +329.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 21 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores VistaGen Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VTGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +329.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Dec 2025 | Jefferies | Downgrade | Hold | $15 → $0.90 |
| 17 Dec 2025 | Maxim Group | Downgrade | Hold | — |
| 17 Dec 2025 | William Blair | Downgrade | Market Perform | — |
| 7 Dec 2023 | Jefferies | Upgrade | Buy | — |
| 14 Nov 2023 | Stifel | Initiates | Buy | — |
| 5 Sept 2023 | Maxim Group | Maintains | Buy | — |
| 7 Aug 2023 | Maxim Group | Upgrade | Buy | — |
| 26 July 2022 | Maxim Group | Downgrade | Hold | — |
| 22 July 2022 | William Blair | Downgrade | Market Perform | — |
| 20 May 2021 | Baird | Initiates | Outperform | — |
| 18 Feb 2021 | Jefferies | Initiates | Buy | — |
| 4 Jan 2021 | William Blair | Upgrade | Outperform | — |
| 8 Oct 2020 | Aegis Capital | Initiates | Buy | — |
| 28 Aug 2019 | William Blair | Initiates | Outperform | — |
| 22 July 2019 | Chardan Capital | Downgrade | Neutral | $22 → $0.70 |
| 27 June 2018 | Maxim Group | Initiates | Buy | — |
| 24 May 2018 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 21 Sept 2026, VistaGen Therapeutics, Inc. returned −92.2% against +17.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 29% of US stocks
Cheaper than 86% of US stocks
Cheaper than 59% of US stocks
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
VistaGen Therapeutics, Inc. has a market value of $10.7M and an enterprise value of −$20.3M.
Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter grew 504.9% year on year.
Net income over the same four quarters: −$67.6M, a −2702.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$62.4M.
Trailing P/E: −0.1×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
VistaGen Therapeutics, Inc. employs 41 people — $61K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own VistaGen Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vistagen announced it will present a poster at Psych Congress 2026 highlighting a positive efficacy signal for its fasedienol nasal spray in study participants with very severe social anxiety disorder.
Why it matters — The presentation of a positive efficacy signal for fasedienol in the most severe patient population could help advance Vistagen's pipeline for social anxiety disorder.
Vistagen reported its fiscal year 2027 first quarter financial results and provided a corporate update. Exploratory analyses of patients with very severe social anxiety disorder showed nominally statistically significant improvement in recently reported clinical studies.
Why it matters — VTGN watchers would care because the positive exploratory data in very severe social anxiety disorder could signal a potential pathway for the company's lead clinical program.
Vistagen announced topline results from its exploratory Phase 2 repeat dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder in adults. The repeat dose demonstrated favorable safety and tolerability similar to single dose, with efficacy signals across primary and secondary endpoints and a prespecified analysis showing nominally statistically significant improvement in patients with very severe social anxiety disorder.
Why it matters — The results provide additional supportive evidence for Vistagen's planned discussions with the FDA regarding the fasedienol registrational pathway, a key step for the company's lead product candidate.
Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience therapies.
Why it matters — A new board appointment may signal fresh strategic oversight as Vistagen advances its pherine-based intranasal product candidates through clinical development.
The 4 Wall Street analysts covering VistaGen Therapeutics, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering VistaGen Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VistaGen Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 21 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Sept 2026, VistaGen Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +329.2% from the last close, and Ticker Nerd's factor model ranks VistaGen Therapeutics, Inc. 28 out of 100 as at 21 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering VistaGen Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.
VistaGen Therapeutics, Inc. returned -92.2% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders.
The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Vistagen to Present at Psych Congress 2026". Vistagen announced it will present a poster at Psych Congress 2026 highlighting a positive efficacy signal for its fasedienol nasal spray in study participants with very severe social anxiety disorder.
Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders. The company develops intranasal product candidates known as pherines, designed to act through nose-to-brain neurocircuitry and support rapid, targeted delivery within the central nervous system. Its current pipeline centers on treatments for conditions such as social anxiety disorder, major depressive disorder, and menopause-related vasomotor symptoms. Vistagen Therapeutics Inc. also pursues research and development using human neuroscience and clinical testing to advance non-systemic therapeutic approaches. Headquartered in South San Francisco, California, the company operates in the biotechnology sector and works to address unmet needs across mental health and women’s health markets.
CEO Mr. Shawn K. Singh J.D. · 41 employees · United States · https://www.vistagen.com
